Weight loss is not always the most helpful starting point. Why Just Try It Is Not Informed Care GLP-1 medications are sometimes framed as low-risk experiments
GLP-1 receptor agonist medications are designed to mimic or activate that same pathway
As DPP-4 inhibitors may not be sufficient in the presence of suppressed GLP-1 secretion form intestinal L-cells, we and others assume that GLP-1 analogs are superior for the management of pasireotide-induced hyperglycemia 27
CANNOT HAVE USED ANY GLP-1s IN PAST 60 DAYS
Obesity - Treatment
2, the meta-analysis of all available cohorts showed a significant reduction in risk for schizophrenia (OR = 0.72, 95% CI [0.610.86]), bipolar disorder (OR = 0.91, 95% CI [0.880.94]), bulimia nervosa (OR = 0.34, 95% CI [0.230.52]), PTSD (OR = 0.45, 95% CI [0.310.67]), and autism (OR = 0.55, 95% CI [0.320.93])